These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38428974)

  • 1. Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study.
    Dougados M; Lardy-Cléaud A; Desfleurs E; Claudepierre P; Goupille P; Ryussen-Witrand A; Saraux A; Tournadre A; Wendling D; Lukas C
    RMD Open; 2024 Feb; 10(1):. PubMed ID: 38428974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA).
    Dougados M; Lucas J; Desfleurs E; Claudepierre P; Goupille P; Ruyssen-Witrand A; Saraux A; Tournadre A; Wendling D; Lukas C
    RMD Open; 2023 Mar; 9(1):. PubMed ID: 36921980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug retention rate and predictive factors of drug survival for secukinumab in radiographic axial spondyloarthritis.
    Armağan B; Kılıç L; Farisoğulları B; Yardımcı GK; Bilgin E; Bölek EÇ; Karadağ Ö; Bilgen ŞA; Kiraz S; Ertenli İ; Kalyoncu U
    Rheumatol Int; 2023 Jan; 43(1):147-156. PubMed ID: 36129541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice.
    Christiansen SN; Horskjær Rasmussen S; Pons M; Michelsen B; Glintborg B; Gudbjornsson B; Grondal G; Vencovsky J; Loft AG; Rotar Z; Pirkmajer KP; Nissen MJ; Baranová J; Macfarlane GJ; Jones GT; Iannone F; Caporali R; Laas K; Vorobjov S; Giuseppe DD; Olofsson T; Provan SA; Fagerli KM; Castrejon I; Otero-Varela L; van de Sande M; van der Horst-Bruinsma I; Nordström D; Kuusalo L; Bernardes M; Hetland ML; Østergaard M; Midtbøll Ørnbjerg L
    Semin Arthritis Rheum; 2024 Apr; 65():152388. PubMed ID: 38301349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Four-year real-world experience of secukinumab in a large Italian cohort of axial spondyloarthritis.
    Ramonda R; Lorenzin M; Chimenti MS; D'Angelo S; Marchesoni A; Selmi C; Lubrano E; Santo L; Luchetti Gentiloni MM; Atzeni F; Cauli A; Manara M; Rossini M; Foti R; Cozzi G; Scagnellato L; Ferraioli M; Carriero A; Luciano N; Ruzzon F; Fatica M; Fracassi E; Doria A; Foti R; Carletto A
    Front Immunol; 2024; 15():1435599. PubMed ID: 39076975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration.
    Michelsen B; Lindström U; Codreanu C; Ciurea A; Zavada J; Loft AG; Pombo-Suarez M; Onen F; Kvien TK; Rotar Z; Santos MJ; Iannone F; Hokkanen AM; Gudbjornsson B; Askling J; Ionescu R; Nissen MJ; Pavelka K; Sanchez-Piedra C; Akar S; Sexton J; Tomsic M; Santos H; Sebastiani M; Österlund J; Geirsson AJ; Macfarlane G; van der Horst-Bruinsma I; Georgiadis S; Brahe CH; Ørnbjerg LM; Hetland ML; Østergaard M
    RMD Open; 2020 Sep; 6(3):. PubMed ID: 32950963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Retention and Clinical Effectiveness of Secukinumab for Axial Spondyloarthritis: Results From the Canadian Spondyloarthritis Research Network.
    Inman RD; Choquette D; Khraishi M; Gladman DD; Hussein S; Neish D; Leclerc P
    J Rheumatol; 2023 May; 50(5):634-640. PubMed ID: 36642434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of disease activity outcome measures reporting in the medical records of patients with axial spondyloarthritis on the retention rates of biological treatment: the example of secukinumab use in daily practice in France.
    Dougados M; Lucas J; Desfleurs E; Lukas C; Saraux A; Tournadre A; Ruyssen-Witrand A; Wendling D; Goupille P; Claudepierre P
    RMD Open; 2022 Mar; 8(1):. PubMed ID: 35301266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
    Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
    Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses.
    Glintborg B; Lindström U; Giuseppe DD; Provan SA; Gudbjornsson B; Hetland ML; Michelsen B; Wallman JK; Aaltonen K; Hokkanen AM; Nordström D; Jørgensen TS; Hansen RL; Geirsson AJ; Grøn KL; Krogh NS; Askling J; Kristensen LE; Jacobsson LTH;
    Arthritis Care Res (Hoboken); 2022 May; 74(5):748-758. PubMed ID: 33253491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Survival, Effectiveness and Safety of Secukinumab in Axial Spondyloarthritis up to 4 Years: A Real-Life Single Center Experience.
    Diaconu AD; Pomîrleanu C; Russu M; Strugariu G; Ancuța E; Ciortescu I; Bologa C; Morărașu BC; Constantin M; Ceasovschih A; Șorodoc V; Șorodoc L; Ancuța C
    J Pers Med; 2024 Apr; 14(4):. PubMed ID: 38673044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry.
    Michelena X; Zhao SS; Dubash S; Dean LE; Jones GT; Marzo-Ortega H
    Rheumatology (Oxford); 2021 Dec; 60(12):5795-5800. PubMed ID: 33502476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retention rate and effectiveness of secukinumab vs TNF inhibitor in ankylosing spondylitis patients with prior TNF inhibitor exposure.
    Min HK; Kim HR; Lee SH; Hong YS; Kim MY; Park SH; Kang KY
    Rheumatology (Oxford); 2021 Dec; 60(12):5743-5752. PubMed ID: 33725088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials.
    Dougados M; Kiltz U; Kivitz A; Pavelka K; Rohrer S; McCreddin S; Quebe-Fehling E; Porter B; Talloczy Z
    Rheumatol Int; 2022 Feb; 42(2):205-213. PubMed ID: 34773130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum.
    Sivera F; Núñez-Monje V; Campos-Fernández C; Balaguer-Trull I; Robustillo-Villarino M; Aguilar-Zamora M; Garijo-Bufort M; López-Gómez JM; Peña-González C; de la Morena I; Bedoya-Sanchís D; Yankova-Komsalova L; Conesa-Mateos A; Martínez-Cristóbal A; Navarro-Blasco FJ; Senabre-Gallego JM; Alegre-Sancho JJ
    Front Med (Lausanne); 2023; 10():1156557. PubMed ID: 37250652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort.
    Micheroli R; Tellenbach C; Scherer A; Bürki K; Niederman K; Nissen MJ; Zufferey P; Exer P; Möller B; Kyburz D; Ciurea A
    Ann Rheum Dis; 2020 Sep; 79(9):1203-1209. PubMed ID: 32581090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world effectiveness and rheumatologist satisfaction with secukinumab in the treatment of patients with axial spondyloarthritis.
    Kiltz U; Keininger DL; Holdsworth EA; Booth N; Howell O; Modi N; Tian H; Conaghan PG
    Clin Rheumatol; 2022 Feb; 41(2):471-481. PubMed ID: 34800174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study.
    Ramonda R; Lorenzin M; Sole Chimenti M; D'Angelo S; Marchesoni A; Salvarani C; Lubrano E; Costa L; Dal Bosco Y; Fracassi E; Ortolan A; Ferraioli M; Carriero A; Visalli E; Bixio R; Desiati F; Bergamini A; Pedrollo E; Doria A; Foti R; Carletto A
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X221090310. PubMed ID: 35510168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
    Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
    Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First Biologic Drug Persistence in Patients With Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: A Real-World Canadian Physicians' Experience.
    Ngo MD; Zummer M; Andersen KM; Richard N
    J Clin Rheumatol; 2022 Jan; 28(1):e210-e216. PubMed ID: 33394832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.